Guardant Health (GH) analyst forecast and price target
Analyst forecast
Consensus of 29 analyst ratings
Based on 13 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Overweight | $200.00 from $185.00 | Oct 13, 2026 |
| Barclays | Maintained | Overweight | $220.00 from $200.00 | Oct 7, 2026 |
| Guggenheim | Maintained | Buy | $200.00 from $190.00 | Oct 1, 2026 |
| UBS | Maintained | Buy | $225.00 from $175.00 | Sep 9, 2026 |
| Rothschild & Co | Initiated Coverage | Buy | $203.00 | Sep 8, 2026 |
| BTIG | Maintained | Buy | $195.00 | Sep 2, 2026 |
| Stephens & Co. | Maintained | Overweight | $195.00 from $170.00 | Aug 4, 2026 |
| Piper Sandler | Maintained | Overweight | $193.00 from $135.00 | Aug 4, 2026 |
| Morgan Stanley | Maintained | Overweight | $185.00 from $175.00 | Aug 4, 2026 |
| Stifel | Maintained | Buy | $180.00 from $130.00 | Aug 3, 2026 |
| BTIG | Maintained | Buy | $195.00 from $190.00 | Jul 31, 2026 |
| Barclays | Maintained | Overweight | $200.00 from $150.00 | Jul 31, 2026 |
| TD Cowen | Maintained | Buy | $210.00 from $200.00 | Jul 31, 2026 |
| JP Morgan | Maintained | Overweight | $195.00 from $185.00 | Jul 31, 2026 |
| Mizuho | Maintained | Outperform | $200.00 from $175.00 | Jul 31, 2026 |
| RBC Capital | Maintained | Outperform | $200.00 from $185.00 | Jul 31, 2026 |
| Guggenheim | Maintained | Buy | $190.00 from $160.00 | Jul 16, 2026 |
| Canaccord Genuity | Maintained | Buy | $205.00 from $135.00 | Jul 14, 2026 |
| Morgan Stanley | Maintained | Overweight | $175.00 from $130.00 | Jul 9, 2026 |
| Citigroup | Maintained | Buy | $215.00 from $150.00 | Jul 8, 2026 |
Frequently asked questions
What is the price target for GH stock?
The average 12-month analyst price target for Guardant Health (GH) is $201.23, with a high estimate of $225.00 and a low of $180.00, across 13 analysts.
Is GH a buy, sell, or hold?
Analysts covering Guardant Health currently average a Buy rating: 25 buy, 3 hold and 1 sell, from 29 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for GH?
The average price target of $201.23 implies 20.84% upside from the last price of $166.52.
What is the latest analyst rating on GH?
On Oct 13, 2026, Morgan Stanley maintained Guardant Health at Overweight with a price target of $200.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.